ArticleProbiotics and antimicrobial proteins2019
Anti-Influenza Activity of Enterocin B In vitro and Protective Effect of Bacteriocinogenic Enterococcal Probiotic Strain on Influenza Infection in Mouse Model.
Article in Probiotics and antimicrobial proteins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies.European journal of nutrition · 2021Pooled it
- Elongation Factor Thermo Unstable Secreted Protein from Ligilactobacillus murinus 0516 Against Avian Infectious Bronchitis Virus.Probiotics and antimicrobial proteins · 2026Article
- Lactic Acid Bacteria Isolated from Traditional Dry-Cured Fermented Foods with Probiotic Effect: Selection, Mechanisms of Action and Applications.Foods (Basel, Switzerland) · 2025Review
- Exploring the Therapeutic Landscape of Probiotics in Enteric and Respiratory Viral Infections.Probiotics and antimicrobial proteins · 2025Review
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Probiotic therapy, African fermented foods and food-derived bioactive peptides in the management of SARS-CoV-2 cases and other viral infections.Biotechnology reports (Amsterdam, Netherlands) · 2023Review
- Potential probiotics for regulation of the gut-lung axis to prevent or alleviate influenza in vulnerable populations.Journal of traditional and complementary medicine · 2023Review
- Screening of bacteriocin-producing dairyFrontiers in microbiology · 2023Article
- Review
- Probiotic-Based Bacteriocin: Immunity Supplementation Against Viruses. An Updated Review.Frontiers in microbiology · 2022Review
- Antiviral Effects and Underlying Mechanisms of Probiotics as Promising Antivirals.Frontiers in cellular and infection microbiology · 2022Review
- Developing a Live Probiotic Vaccine Based on theMicroorganisms · 2021Article
- A Live Probiotic Vaccine Prototype Based on Conserved Influenza a Virus Antigens Protect Mice against Lethal Influenza Virus Infection.Biomedicines · 2021Article
- The Interaction Between Viruses and Intestinal Microbiota: A Review.Current microbiology · 2021Review
- Antiviral activity of fermented foods and their probiotics bacteria towards respiratory and alimentary tracts viruses.Food control · 2021Review
- Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes.Advances in nutrition (Bethesda, Md.) · 2021Review
- Genome Mining for Antimicrobial Compounds in Wild Marine Animals-Associated Enterococci.Marine drugs · 2021Article
- Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs).Cellular and molecular life sciences : CMLS · 2021Review
- The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?Microbial pathogenesis · 2020Review
- Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances.International journal of environmental research and public health · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In spite of scientific evidence demonstrating the antiviral activity of lactic-acids bacteria, little is known about the mechanism of their action. Previously, several bacteriocins isolated from lactic acid bacteria (LAB) and some other microorganisms were reported as having antiviral activity in vitro. In the present study, chemically synthetized enterocin B (EntB) and the strain E. faecium L3, known as the producer of this peptide, were tested for activity against influenza viruses. The inhibition of cytopathic effect of А/Perth/16/2009(H3N2) and A/South Africa/3626/2013(H1N1) pdm influenza viruses in MDCK cells by chemically synthetized EntB was revealed. The EntB demonstrated antiviral activity at a concentration of 2.5-5 μg/ml depending on the dose of viruses. This peptide exhibited low toxicity in MDCK cells, causing partial damage of the monolayer of the cells only at a concentration above 10 μg/ml. It was also shown, that strain E. faecium L3-protected mice from lethal A/South Africa/3626/2013(H1N1) pdm infection. We speculate that this protective effect of enterococci may be associated with the specific action of enterocin B, which possesses antiviral activity in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.